Stay updated with breaking news from Nasdaq Prld. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Prelude Therapeutics (NASDAQ:PRLD – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Friday, Zacks.com reports. According to Zacks, “Prelude Therapeutics Incorporated is a clinical-stage precision oncology company. It is focused on discovering and developing small molecule therapies optimized to […]
Prelude Therapeutics Incorporated (NASDAQ:PRLD – Get Rating) CFO Laurent Chardonnet acquired 10,000 shares of Prelude Therapeutics stock in a transaction dated Wednesday, June 1st. The shares were bought at an average price of $4.23 per share, with a total value of $42,300.00. Following the transaction, the chief financial officer now directly owns 24,500 shares in […]
Brokerages expect Prelude Therapeutics Incorporated (NASDAQ:PRLD – Get Rating) to report ($0.68) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for Prelude Therapeutics’ earnings. The highest EPS estimate is ($0.64) and the lowest is ($0.76). Prelude Therapeutics posted earnings of ($0.47) per share in the same quarter […]
Prelude Therapeutics (NASDAQ:PRLD – Get Rating) issued its quarterly earnings data on Wednesday. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.03), Fidelity Earnings reports. Shares of PRLD stock opened at $8.36 on Friday. The firm has a fifty day moving average price of $9.35 […]
Prelude Therapeutics (NASDAQ:PRLD – Get Rating) was downgraded by research analysts at Bank of America from a “buy” rating to a “neutral” rating in a report issued on Tuesday, MarketBeat reports. They currently have a $10.00 price objective on the stock, down from their previous price objective of $50.00. Bank of America‘s price objective points […]